Molecular and therapeutic apploaches of autosomal recessive familial Alzheimer's disease using APPE693dlta-iPS cells.

Molecular and therapeutic apploaches of autosomal recessive familial Alzheimer's disease using APPE693dlta-iPS cells. - Analysis of disease-causing mutant APP (E693delta) iPS cells

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017836

Enrollment

Registered

2015-06-08

Start date

2015-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Alzheimer&#39

Interventions

Introduction of Yamanaka&#39

s factor into patient-derived somatic cells.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients havoring APP-E693delta

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Establishment of the iPS cells from a patient with familial Alzheimer's disease(APP E693delta).	—

Secondary

Measure	Time frame
Screening of small-molecule inhibitors preventing familial Alzheimer's disease(APP E693delta).	—

Countries

Japan

Contacts

Public ContactYoshihide Sunada

Kawasaki Medical School Neurology

ysunada@med.kawasaki-m.ac.jp0864621111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Molecular and therapeutic apploaches of autosomal recessive familial Alzheimer&#39;s disease using APPE693dlta-iPS cells.